[go: up one dir, main page]

CA2185353A1 - Traitement de maladies auto-immunes utilisant la tolerance orale et/ou l'interferon de type i - Google Patents

Traitement de maladies auto-immunes utilisant la tolerance orale et/ou l'interferon de type i

Info

Publication number
CA2185353A1
CA2185353A1 CA002185353A CA2185353A CA2185353A1 CA 2185353 A1 CA2185353 A1 CA 2185353A1 CA 002185353 A CA002185353 A CA 002185353A CA 2185353 A CA2185353 A CA 2185353A CA 2185353 A1 CA2185353 A1 CA 2185353A1
Authority
CA
Canada
Prior art keywords
ifn
disease
cells
antigen
bystander
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002185353A
Other languages
English (en)
Inventor
David A. Hafler
Howard L. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2185353A1 publication Critical patent/CA2185353A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rehabilitation Therapy (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)

Abstract

L'invention concerne des méthodes de traitement de maladies auto-immunes telles que la sclérose en plaques par l'administration par voie orale d'un antigène "bystander" tel qu'une protéine myélinique de base ou protéolipidique conjointement avec un polypeptide présentant l'activité de l'interféron de type I de sorte qu'une tolérance orale soit induite vis-à-vis de l'antigène "bystander" et entraîne la suppression de la réponse auto-immune.
CA002185353A 1994-04-08 1995-04-07 Traitement de maladies auto-immunes utilisant la tolerance orale et/ou l'interferon de type i Abandoned CA2185353A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
US225,372 1994-04-08

Publications (1)

Publication Number Publication Date
CA2185353A1 true CA2185353A1 (fr) 1995-10-19

Family

ID=22844605

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002185353A Abandoned CA2185353A1 (fr) 1994-04-08 1995-04-07 Traitement de maladies auto-immunes utilisant la tolerance orale et/ou l'interferon de type i

Country Status (9)

Country Link
EP (1) EP0752880A4 (fr)
JP (1) JPH09511745A (fr)
AU (1) AU686797B2 (fr)
BR (1) BR9507451A (fr)
CA (1) CA2185353A1 (fr)
HU (1) HUT74900A (fr)
IL (1) IL113303A0 (fr)
NO (1) NO964199D0 (fr)
WO (1) WO1995027499A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
HUT77047A (hu) * 1994-10-25 1998-03-02 Immulogic Pharmaceutical Corporation Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
JP2001511187A (ja) * 1997-02-28 2001-08-07 エンゾー セラピュウティクス， インコーポレイテッド 選択的免疫ダウンレギュレーション（ｓｉｄｒ）を行う新規プロセス
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
AU2001249214A1 (en) 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
EP1286686B1 (fr) 2000-05-24 2007-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES E-selectin pour le traitement ou la prevention des accidents vasculaires cerebraux
US7449177B2 (en) 2002-12-26 2008-11-11 Asubio Pharma Co., Ltd. Remedy for pemphigoid
EP2572734B1 (fr) 2006-10-31 2016-04-06 East Carolina University Protéines de fusion à base de cytokine pour le traitement des troubles immunitaires
EP3348275A3 (fr) 2009-03-31 2018-10-24 East Carolina University Cytokines et neuroantigènes utilisés dans le traitement de troubles immunitaires
JP6590330B2 (ja) * 2013-11-11 2019-10-16 キッコーマン株式会社 経口免疫寛容増強物質のスクリーニング方法および経口免疫寛容増強組成物
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2844889A (en) * 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells
EP0627933B1 (fr) * 1992-02-28 2002-11-27 Autoimmune, Inc. Suppression de maladies auto-immunes par des antigenes en attente

Also Published As

Publication number Publication date
IL113303A0 (en) 1995-07-31
HU9602750D0 (en) 1996-11-28
BR9507451A (pt) 1997-08-05
NO964199L (no) 1996-10-03
AU2277695A (en) 1995-10-30
EP0752880A4 (fr) 2000-08-09
WO1995027499A1 (fr) 1995-10-19
JPH09511745A (ja) 1997-11-25
HUT74900A (en) 1997-02-28
AU686797B2 (en) 1998-02-12
NO964199D0 (no) 1996-10-03
EP0752880A1 (fr) 1997-01-15

Similar Documents

Publication Publication Date Title
AU720695B2 (en) Bystander suppression of autoimmune diseases
US6645504B1 (en) Bystander suppression of type I diabetes by oral administration of glucagon
Miller et al. Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression.
US6036957A (en) Suppression of T-cell proliferation using peptide fragments of myelin basic protein
US5935577A (en) Treatment of autoimmune disease using tolerization in combination with methotrexate
WO1998032451A9 (fr) Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate
KR20000070460A (ko) 메토트렉세이트와 공동으로 내성화를 사용한 자기면역질병의 치료
CA2185353A1 (fr) Traitement de maladies auto-immunes utilisant la tolerance orale et/ou l'interferon de type i
AU695883B2 (en) Treatment of autoimmune disease using oral tolerization and/or Th2-enhancing cytokines
WO1999056763A9 (fr) Utilisation d'antigenes tissulaires cibles, negliges, pour moduler les reactions immunitaires
US20010007758A1 (en) Treatment of multiple sclerosis using COP-1 and Th2-enhancing cytokines
AU6058390A (en) Methods of treating or preventing autoimmune uveoretinitis in mammals
US20040115217A1 (en) Bystander suppression of autoimmune diseases
HK1253094A1 (zh) 多肽组合物
JPH11514847A (ja) 糖尿病の処置および予防のための方法

Legal Events

Date Code Title Description
FZDE Discontinued